Cardiac MRI demonstrated a significantly increased myocardial extracellular volume fraction in hypertensive patients compared to normotensive controls (0.34 vs. 0.24, p<0.0001).
Observational (n=19)
No
Does 3T cardiac MRI with T1 mapping detect increased myocardial extracellular volume fraction in hypertensive patients with LVH compared to normotensive controls?
Cardiac MRI T1 mapping identifies increased myocardial extracellular volume fraction in hypertensive patients with LVH, suggesting it can detect diffuse fibrosis before replacement fibrosis occurs.
Absolute Event Rate: 0.34% vs 0.24%
p-value: p=<0.0001
Background Left ventricular hypertrophy (LVH) is an important marker of adverse prognosis in cardiovascular disease and commonly occurs in association with hypertension. While late gadolinium enhancement (LGE) reflects myocardial replacement fibrosis in hypertensive patients, we hypothesized that the myocardial extracellular volume fraction (MECVF) would better reflect the presence and severity of myocardial fibrosis, including diffuse fibrosis, in hypertensive patients with LVH. We sought to measure the MECVF directly using T1 imaging preand post-contrast.
Mongeon et al. (Wed,) conducted a observational in Systemic hypertension with left ventricular hypertrophy (n=19). Cardiac MRI for MECVF quantification vs. Normotensive controls was evaluated on Myocardial extracellular volume fraction (MECVF) (p=<0.0001). Cardiac MRI demonstrated a significantly increased myocardial extracellular volume fraction in hypertensive patients compared to normotensive controls (0.34 vs. 0.24, p<0.0001).